抗性突变
恩曲他滨
病毒准种
拉米夫定
突变
病毒载量
病毒学
养生
医学
内科学
生物
人类免疫缺陷病毒(HIV)
遗传学
逆转录酶
抗逆转录病毒疗法
核糖核酸
病毒
丙型肝炎病毒
基因
乙型肝炎病毒
作者
Elisa Teyssou,Cathia Soulié,Antoine Fauchois,Romain Palich,A. Nouchi,Sophie Sayon,Basma Abdi,Marc Wirden,Christine Katlama,Valérie Pourcher,Anne‐Geneviève Marcelin,Vincent Cálvez
摘要
Abstract Objectives Resistance associated mutations (RAMs) are archived in the HIV reservoir and can re-emerge with an inappropriate ART use limiting treatment options. However, recent studies, using ultra-deep sequencing (UDS), showed a decrease of quasispecies harbouring RAMs, suggesting that recycling some antiretrovirals could be considered. The aim of this study was to characterize, in HIV treated PLWHIV, the M184V mutation decrease kinetics in proviral DNA and associated factors of M184V mutation clearance over time. Methods UDS was performed on HIV-DNA from blood cells at different time points to quantify the percentage of M184V positive quasispecies. The sequence reads were analysed with a minimum coverage set at 50 and an ambiguity filter at 5% or 2%. Results At 2.5 years after the first time point, the M184V lost was observed in 50% of PLWHIV. Moreover, univariate analyses highlight that a higher nadir CD4 count and a lower zenith HIV1 RNA viral load were correlated with a faster clearance of the mutation. In multivariate analysis, a higher zenith was negatively associated with the M184V clearance at the 5% threshold. Interestingly, lamivudine/emtricitabine presence in the ART therapy regiment during the 5 years was not associated with the persistence of the M184V. Conclusions Our study provides new information concerning the clearance speed of M184V mutation over time in PLWHIV with fully suppressed viremia, opens the discussion about the duration needed to consider a lamivudine/emtricitabine recycling and reinforces the association of the nadir and zenith values with the M184V mutation clearance.
科研通智能强力驱动
Strongly Powered by AbleSci AI